LINC01482: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01482

NCBI ID: G101928104

LINC01482

Other Name(s): long intergenic non-protein coding RNA 1482 | Long intergenic non-protein coding RNA 1482

LINC01482: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01482 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and has been implicated in various biological processes. recent studies have identified LINC01482 as a potential drug target and biomarker. In this article, we will provide an overview of LINC01482, its potential drug target status, and its potential as a biomarker for various diseases.

Overview of LINC01482

LINC01482 is a transcribed RNA molecule that is longer than 200 nucleotides. It is primarily expressed in the brain and is involved in various cellular processes. LINC01482 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

LINC01482 has been shown to interact with several proteins, including the protein SMY/TCP and the RNA-protein complex known as RNA-protein interactions (RISC). These interactions suggest that LINC01482 may be a protein target or a biomarker that can be used to monitor the effects of drugs on these interactions.

Potential Drug Target

The potential drug target for LINC01482 is its interaction with SMY/TCP, a protein that is known to play a role in the regulation of cell division and growth. LINC01482 has been shown to interact with SMY/TCP and regulate the stability of the protein, which suggests that it may be a drug target for diseases that are characterized by the over-expression or dysfunction of SMY/TCP.

In addition to its interaction with SMY/TCP, LINC01482 has also been shown to interact with the protein heat shock protein (Hsp70), which is involved in the regulation of protein folding and stability. This interaction suggests that LINC01482 may be a drug target for diseases that are characterized by the over-expression or dysfunction of Hsp70.

Potential Biomarker

LINC01482 has also been shown to be involved in the regulation of cellular processes, including cell adhesion and migration. This suggests that it may be a biomarker for diseases that are characterized by the disruption of these processes, such as cancer. In addition, LINC01482 has also been shown to play a role in the regulation of the immune response, which suggests that it may be a biomarker for diseases that are characterized by the disruption of this process, such as autoimmune diseases.

Conclusion

In conclusion, LINC01482 is a long non-coding RNA that has been identified in various organisms, including humans. It is characterized by its ability to interact with proteins and has been implicated in various biological processes. Recent studies have identified LINC01482 as a potential drug target and biomarker. Its interaction with the protein SMY/TCP and the RNA-protein complex known as RNA-protein interactions (RISC) suggests that LINC01482 may be a drug target for diseases that are characterized by the over-expression or dysfunction of SMY/TCP and Hsp70. In addition, its involvement in the regulation of cellular processes, including cell adhesion and migration, suggests that it may be a biomarker for diseases that are characterized by the disruption of these processes, such as cancer and autoimmune diseases. Further studies are needed to confirm these potential applications of LINC01482.

Protein Name: Long Intergenic Non-protein Coding RNA 1482

The "LINC01482 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01482 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets